Sanofi (SNYNF)
OTHER OTC:SNYNF
SNYNF Stock Chart & Stats
$89.85
$0.00(0.00%)
At close: 4:00 PM EST
$89.85
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$85.74 - $116.51
Previous CloseN/A
Volume2.00
Average Volume (3M)7.42K
Market Cap
$111.47B
Enterprise Value$110.46B
Total Cash (Recent Filing)$7.66B
Total Debt (Recent Filing)$21.80B
Price to Earnings (P/E)12.9
Beta0.22
Next Earnings
Apr 23, 2026EPS Estimate
2.05Next Dividend Ex-DateN/A
Dividend Yield4.57%
Share Statistics
EPS (TTM)1.77
Shares Outstanding1,212,182,500
10 Day Avg. Volume558
30 Day Avg. Volume7,422
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.41
Price to Sales (P/S)2.31
P/FCF Ratio11.23
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue2.45
Enterprise Value/Gross Profit3.45
Enterprise Value/Ebitda16.11
Forecast
1Y Price Target
$108.18Price Target Upside20.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)9.77
Revenue Forecast (FY)$55.55B
Bulls Say, Bears Say
Bulls Say
Capital Allocation And Currency TailwindsManagement guidance is supported by favorable currency movements and a substantial share buyback program that can boost earnings per share without relying on large sales surprises.
Flagship Product GrowthAnalyst expects Dupixent to drive stronger sales as faster adoption of biologic treatments in eczema and effective lifecycle management expand market opportunities.
Leadership ChangeAnalyst believes a new CEO can unlock value by enabling more impactful strategic levers and major shareholders are amenable to change.
Bears Say
Clinical Trial Performance And Near-term Catalyst RiskRecent late-stage trial results failed to meet original efficacy targets for some programs, creating uncertainty about approvals and leaving the near-term outlook light on clear catalysts for investors.
Pipeline Approval RiskAnalyst highlights that non-approval of amlitelimab would be the largest downside risk, making pipeline setbacks a key threat to the investment case.
Regulatory SetbackThe FDA issued a complete response letter for tolebrutinib, representing a significant regulatory setback that alters approval prospects and investor expectations.
Sanofi News
SNYNF FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest stock price was $85.74 and its highest was $116.51 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is $111.47B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Apr 23, 2026 which is in 28 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Jan 29, 2026. The company reported $1.769 earnings per share for the quarter, beating the consensus estimate of $1.675 by $0.095.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi pays a Annually dividend of $4.41 which represents an annual dividend yield of 4.57%. See more information on Sanofi dividends here
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 2.05.
How many shares outstanding does Sanofi have?
Sanofi has 1,212,182,500 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of $1.769 in its last earnings report, beating expectations of $1.675. Following the earnings report the stock price went up 0.574%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in SNYNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
SNYNF Company Deck
SNYNF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong financial and commercial execution in 2025, with robust top-line growth, margin expansion, cash generation, multiple high-impact product launches, and extensive pipeline progress and regulatory approvals. Notable challenges include a Phase III failure (tolebrutinib for PPMS), a safety signal (single Kaposi sarcoma case) requiring monitoring, reductions in Regeneron R&D reimbursement with medium-term BOI implications, and uncertainty in the vaccine market driven by recent U.S. schedule changes. On balance, the company’s positive financial results, successful launches, active BD/investment strategy, and constructive pipeline readouts outweigh the material but manageable challenges.View all SNYNF earnings summariesSNYNF Stock 12 Month Forecast
Average Price Target
$108.18
▲(20.40% Upside)
Technical Analysis
Ownership Overview
―
Insiders
14.79% Mutual Funds
<0.01% Other Institutional Investors
70.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---